Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

By sjmartinez • February 8, 2023

Borghaei H, Ciuleanu TE, Lee JS, Pluzanski A, Caro RB, Gutierrez M, Ohe Y, Nishio M, Goldman J, Ready N, Spigel DR, Ramalingam SS, Paz-Ares LG, Gainor JF, Ahmed S, Reck M, Maio M, O'Byrne KJ, Memaj A, Nathan F, Tran P, Hellmann MD, Brahmer JR. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Ann Oncol. 2023 Feb;34(2):173-185. doi: 10.1016/j.annonc.2022.11.006. Epub 2022 Nov 19. PMID: 36414192.

Tags: dual immunotherapy, Hematology/Oncology, ipilimumab, nivolumab, NSCLC, Publications

[68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions

Ludwig V, Maliha PG, Shen J, Tonnelet D, Raman S, Litwin MS, Calais J. [68Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic[...]

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights

Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update[...]

Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma

Lownik J, Boiarsky J, Birhiray R, Merchant A, Mead M. Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma. Clin Cancer Res.[...]